These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16178505)

  • 21. Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
    Goldstein JL; Bello AE; Spalding W; Suh S; Fort JG
    J Rheumatol; 2005 Jan; 32(1):111-7. PubMed ID: 15630735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
    Cannon CP; Curtis SP; Bolognese JA; Laine L;
    Am Heart J; 2006 Aug; 152(2):237-45. PubMed ID: 16875903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The efficacy and safety of etoricoxib versus meloxicam in the treatment of patients with gonarthrosis].
    Zavodovsky BV; Sivordova LE; Polyakova YV; Akhverdyan YR; Kuznetsova MI; Zborovskaya IA
    Ter Arkh; 2016; 88(12):78-81. PubMed ID: 28139564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The lessons of Vioxx.
    Frazier KC
    N Engl J Med; 2005 Sep; 353(13):1420-1; author reply 1420-1. PubMed ID: 16192497
    [No Abstract]   [Full Text] [Related]  

  • 25. The ever growing story of cyclo-oxygenase inhibition.
    Rodríguez LA; Patrignani P
    Lancet; 2006 Nov; 368(9549):1745-7. PubMed ID: 17113403
    [No Abstract]   [Full Text] [Related]  

  • 26. Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs.
    Nettis E; Colanardi MC; Ferrannini A; Vacca A; Tursi A
    Ann Allergy Asthma Immunol; 2005 Nov; 95(5):438-42. PubMed ID: 16312166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased risk of cardiovascular events with coxibs and NSAIDs.
    Scott DG; Watts RA
    Lancet; 2005 Apr 30-May 6; 365(9470):1537. PubMed ID: 15866299
    [No Abstract]   [Full Text] [Related]  

  • 28. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
    Watson DJ; Bolognese JA; Yu C; Krupa D; Curtis S
    Curr Med Res Opin; 2004 Dec; 20(12):1899-908. PubMed ID: 15701208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [COX-2 inhibitors--one step forward and two steps back].
    Evensen S; Spigset O; Slørdal L
    Tidsskr Nor Laegeforen; 2005 Apr; 125(7):875-8. PubMed ID: 15815733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Etoricoxib in the treatment of chronic pain.
    Duncan MR; Capell HA
    Int J Clin Pract; 2003 May; 57(4):315-8. PubMed ID: 12800464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Etoricoxib (Arcoxia)].
    Leclercq P; Malaise MG
    Rev Med Liege; 2004 May; 59(5):345-9. PubMed ID: 15270001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
    Bingham CO; Sebba AI; Rubin BR; Ruoff GE; Kremer J; Bird S; Smugar SS; Fitzgerald BJ; O'Brien K; Tershakovec AM
    Rheumatology (Oxford); 2007 Mar; 46(3):496-507. PubMed ID: 16936327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP; Curtis SP; FitzGerald GA; Krum H; Kaur A; Bolognese JA; Reicin AS; Bombardier C; Weinblatt ME; van der Heijde D; Erdmann E; Laine L;
    Lancet; 2006 Nov; 368(9549):1771-81. PubMed ID: 17113426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The coxibs, selective inhibitors of cyclooxygenase-2.
    Rich SA
    N Engl J Med; 2001 Dec; 345(23):1709. PubMed ID: 11759657
    [No Abstract]   [Full Text] [Related]  

  • 35. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
    Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Keeping science on top in drug evaluation.
    Avorn J
    N Engl J Med; 2007 Aug; 357(7):633-5. PubMed ID: 17699813
    [No Abstract]   [Full Text] [Related]  

  • 37. Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal.
    Hinz B; Renner B; Brune K
    Nat Clin Pract Rheumatol; 2007 Oct; 3(10):552-60; quiz 1 p following 589. PubMed ID: 17906610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What price pain relief?
    Hochman JS; Shah NR
    Circulation; 2006 Jun; 113(25):2868-70. PubMed ID: 16785335
    [No Abstract]   [Full Text] [Related]  

  • 39. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
    Carracedo-Martínez E
    Pharmacoeconomics; 2005; 23(7):743; author reply 743-5. PubMed ID: 15987231
    [No Abstract]   [Full Text] [Related]  

  • 40. [3 questions about gastrointestinal risk. Are coxibs here clearly better than NSAID?]].
    Krüger K
    MMW Fortschr Med; 2006 Nov; 148(48):12. PubMed ID: 17615761
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.